Impact of tumor burden at progression and changes in risk scores from baseline in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab: phase 3 CLEAR trial
Grünwald, V. ; Keizman, D. ; Bedke, J. ; Staehler, M. D. ; Matveev, V. B. ; George, S. ; Hutson, T. E. ; Vaishampayan, U. N. ; Merchan, J. R. ; Eto, M. ... show 10 more
Grünwald, V.
Keizman, D.
Bedke, J.
Staehler, M. D.
Matveev, V. B.
George, S.
Hutson, T. E.
Vaishampayan, U. N.
Merchan, J. R.
Eto, M.
Citations
Altmetric:
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Grünwald V, Keizman D, Bedke J, Staehler MD, Matveev VB, George S, et al. Impact of tumor burden at progression and changes in risk scores from baseline in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab: phase 3 CLEAR trial. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2025 JUL;21:119-. PubMed PMID: WOS:001552871000037. English.